Abstract
Overexpression or activation of insulin-like growth factor I receptor (IGF-IR) has been observed in many human cancers including breast, lung, colon and gastric carcinomas. We demonstrate that inhibition of the endogenous insulin-like growth factor I receptor by stable expression of a dominant-negative IGF-IR represses the transforming activity in vitro and tumorigenicity of human lung carcinoma cells A549 in vivo. The suppression of tumorigenicity in nude mice is correlated with the induction of glandular differentiation. In addition, functional inhibition of the endogenous receptor dramatically increases the sensitivity of A549 cells to a variety of apoptotic signals including UV irradiation and proteasome inhibitors. These effects are due to the formation of a stable heterocomplex of the dominant-negative receptor with the endogenous wild type receptor which reduces the kinase activity of the latter by twofold. Thus, inhibition of the IGF-IR signaling pathway not only suppresses tumorigenicity but also enhances sensitivity to apoptosis-inducing agents. Antagonizing IGF-IR signaling by promoting tumor differentiation and enhancing sensitivity to apoptotic death are potential cancer therapeutic approaches.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Cantley LC, Auger KR, Carpenter C, Duckworth B, Graziani A, Kapeller R and Soltoff S. . 1991 Cell 64: 281–302.
Copola D, Ferber A, Miura M, Sell C, D'Ambrosio C, Rubin R and Baserga R. . 1994 Mol. Cell. Biol. 14: 4588–4589.
D'Ambrosio C, Ferber A, Resnicoff M and Baserga R. . 1996 Cancer Res. 56: 4013–4020.
D'Ambrosio C, Valentinis B, Prisco M, Reiss K, Rubini M and Baserga R. . 1997 Cancer Res. 57: 3264–3271.
Freed KA and Herington AC. . 1989 J. Mol. Endocrinol. 1: 183–190.
Imajoh-Ohmi S, Kawaguchi T, Sugiyama S, Tanaka K, Omura S and Kikuchi H. . 1995 Biochem. Biophys. Res. Commun. 217: 1070–1077.
Kaleko M, Rutter WJ and Miller AD. . 1990 Mol. Cell. Biol. 10: 464–473.
Kulik G, Klippel A and Weber MJ. . 1997 Mol. Cell. Biol. 7: 1595–1606.
Lee TC, Zhang Y, Aston C, Hintz R, Jagirda J, Perle MA, Burt M and Rom WN. . 1993 Cancer Res. 53: 2858–2864.
Le Roith D. . 1995 Ann. Internal Med. 122: 54–59.
LeRoith D, Werner H, Beitner-Johnson D and Roberts Jr CT. . 1995 Endocr. Rev. 16: 143–163.
Liu D, Rutter WJ and Wang LH. . 1993 J. Virol. 67: 9–18.
Macauley VM, Teale JD, Everard MJ, Joshi GP, Smith IE and Millar JL. . 1988 Br. J. Cancer 57: 91–93.
Nakamura S, Watanabe H, Miura M and Sasaki T. . 1997 Exp. Cell. Res. 235: 287–294.
Nakanishi Y, Mulshine JL, Kasprzyk PG, Natale RB, Maneckjee R, Avis I, Treston AM, Gazdar AF, Minna JD and Cuttitta F. . 1988 J. Clin Invest. 82: 354–359.
Neuenschwander S, Roberts Jr CT and LeRoith D. . 1995 Endocrinology 136: 4298–4303.
O'Connor R, Kauffman-Zeh A, Liu Y, Lehar S, Evan GI, Baserga R and Blattler WA. . 1997 Mol. Cell. Biol. 17: 427–435.
Prager D, Li HL, Asa S and Melmed S. . 1994 Proc. Natl. Acad. Sci. USA 91: 2181–2185.
Randazzo PA, Morey A, Polishook AK and Jaret L. . 1990 Exp. Cell. Res. 190: 25–30.
Resnicoff M, Abraham D, Yutanawiboonchai W, Rotman HL, Kajstura J, Rubin R, Zoltick P and Baserga R. . 1995 Cancer Res. 55: 2463–2469.
Resnicoff M, Coppola D, Sell C, Rubin R, Ferrone S and Baserga R. . 1994 Cancer Res. 54: 4848–4850.
Resnicoff M, Tjuvajev J, Rotman HL, Abraham D, Curtis M, Aiken R and Baserga R. . 1996 J. Exp. Ther. Oncol. 1: 385–389.
Rininsland F, Johnson TR, Chemicky CL, Shulze E, Burfeind P and Ilan J. . 1997 Proc. Natl. Acad. Sci. USA 94: 5854–5859.
Rubin R and Baserga R. . 1995 Lab. Invest. 73: 311–331.
Schlessinger J. . 1988 Trends Biochem. Sci. 13: 443–447.
Sell C, Dumenil G, Deveand C, Miura M, Coppda D, DeAngelis T, Rubin R, Efstratiadis A and Baserga R. . 1994 Mol. Cell. Biol. 14: 3604–3612.
Shimihara K, Tomioka M, Nakano H, Tone S, Ito H and Kawashima S. . 1996 Biochem. J. 317: 385–388.
Singleton JR, Randolph AE and Feldman EL. . 1996 Cancer Res. 56: 4522–4529.
Speirs V, Ray KP and Freshney RI. . 1991 Br. J. Cancer 64: 693–699.
Turner BC, Haffty BG, Narayanan L, Yuan J, Havre PA, Gumbs AA, Kaplan L, Burgaud JL, Carter D, Baserga R and Glazer P. . (1997) Cancer Res. 57: 3079–3083.
Valentinis B, Morrione A, Taylor SJ and Baserga R. . 1997 Mol. Cell. Biol. 17: 3744–3754.
Williams LT. . 1989 Science 243: 1564–1570.
Wu Y, Tewari M, Cui S and Rubin R. . 1996 J. Cell. Physiol. 168: 499–509.
Yarden Y and Schlessinger J. . 1987 Biochemistry 26: 1443–1457.
Yarden Y and Ullrich A. . 1988 Annu. Rev. Biochem. 57: 443–478.
Zong CS, Chan JLK, Yang SK and Wang LH. . 1997 J. Biol. Chem. 272: 1500–1506.
Acknowledgements
We thank Drs Lu-Hai Wang and Hua Cheng for anti-IGF-IR antibody, IGF-IR cDNA and pBEFneo vector, respectively. This work was supported by Lola and Allen Goldring Clinical Scholars Fund (to Y Jiang), National Institutes of Health Grants MO1-RR00096, RO1-HL59832 and 62055 (to WN Rom), and RO1-ES09161 and American Lung Association Research Grant Award (to K-M Tchou-Wong).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Jiang, Y., Rom, W., Yie, TA. et al. Induction of tumor suppression and glandular differentiation of A549 lung carcinoma cells by dominant-negative IGF-I receptor. Oncogene 18, 6071–6077 (1999). https://doi.org/10.1038/sj.onc.1202984
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1202984
Keywords
This article is cited by
-
Reconstruction of gene regulatory networks reveals chromatin remodelers and key transcription factors in tumorigenesis
Genome Medicine (2016)
-
Insulin-like growth factor type I receptor: a new target in the treatment of non-small cell lung cancer patients
memo - Magazine of European Medical Oncology (2010)
-
Effect of type 1 insulin-like growth factor receptor targeted therapy on chemotherapy in human cancer and the mechanisms involved
Journal of Cancer Research and Clinical Oncology (2010)
-
E2F1 induces apoptosis and sensitizes human lung adenocarcinoma cells to death-receptor-mediated apoptosis through specific downregulation of c-FLIPshort
Cell Death & Differentiation (2006)
-
IGF-II induces CREB phosphorylation and cell survival in human lung cancer cells
Oncogene (2005)